^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
RG6353
i
Other names: RG6353, RO7515629
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Roche
Drug class:
CD3 agonist, HLA G inhibitor
Related drugs:
6ms
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors (clinicaltrials.gov)
P1, N=3, Terminated, Hoffmann-La Roche | Phase classification: P1/2 --> P1
Phase classification • Metastases
|
MUC16 (Mucin 16, Cell Surface Associated) • HLA-G (Major Histocompatibility Complex, Class I, G)
|
Actemra IV (tocilizumab) • RG6353
8ms
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors (clinicaltrials.gov)
P1/2, N=3, Terminated, Hoffmann-La Roche | N=150 --> 3 | Trial completion date: Jan 2027 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Mar 2024; Sponsor decision (not related to safety, efficacy or quality).
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
MUC16 (Mucin 16, Cell Surface Associated) • HLA-G (Major Histocompatibility Complex, Class I, G)
|
HLA-G positive
|
Actemra IV (tocilizumab) • RG6353
10ms
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors (clinicaltrials.gov)
P1/2, N=150, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
Enrollment closed
|
MUC16 (Mucin 16, Cell Surface Associated) • HLA-G (Major Histocompatibility Complex, Class I, G)
|
HLA-G positive
|
Actemra IV (tocilizumab) • RG6353
over1year
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors (clinicaltrials.gov)
P1/2, N=150, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
MUC16 (Mucin 16, Cell Surface Associated) • HLA-G (Major Histocompatibility Complex, Class I, G)
|
HLA-G positive
|
Actemra IV (tocilizumab) • RG6353
Share via
